indazoles has been researched along with Squamous Cell Carcinoma of Head and Neck in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brands, RC; De Donno, F; Hartmann, S; Knierim, LM; Kübler, AC; Müller-Richter, UDA; Seher, A; Steinacker, V | 1 |
| Sherman, EJ; Tchekmedyian, V | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Hoshino, D; Maldonado, AT; Tyson, DR; Weaver, AM; Wirtz, ED | 1 |
| Spector, M; Swiecicki, PL; Worden, FP | 1 |
| Ben-Jonathan, N; Kumar, B; Kumar, P; Takiar, V; Tuttle, TR | 1 |
1 review(s) available for indazoles and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Axitinib in the Treatment of Head and Neck Malignancies.
Topics: Axitinib; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Squamous Cell Carcinoma of Head and Neck; Survival; Thyroid Neoplasms | 2016 |
1 trial(s) available for indazoles and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
4 other study(ies) available for indazoles and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.
Topics: Benzimidazoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Indazoles; Indoles; Male; Protein Kinase Inhibitors; Pyrimidines; Quinolones; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2017 |
Targeting VEGF and EGFR: a combination worth re-exploring?
Topics: Cetuximab; ErbB Receptors; Humans; Indazoles; Pyrimidines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; Vascular Endothelial Growth Factor A | 2018 |
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Topics: Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinolines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2015 |
Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Head and Neck Neoplasms; Humans; Indazoles; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyridines; Soluble Guanylyl Cyclase; Squamous Cell Carcinoma of Head and Neck | 2017 |